Request Deal Involvement

Goldman Sachs Asset Management led a $150m Series B funding round in MOMA Therapeutics.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

1AB

pr advisors

1AB

Cooley

legal advisors

Cooley

or

Principals

MOMA THERAPEUTICS

target

MOMA THERAPEUTICS

ROCK SPRINGS CAPITAL

bidder

ROCK SPRINGS CAPITAL

SECTION 32 (S32)

bidder

SECTION 32 (S32)

THIRD ROCK VENTURES LLC

bidder

THIRD ROCK VENTURES LLC

NEXTECH INVEST

bidder

NEXTECH INVEST

GOLDMAN SACHS ASSET MANAGEMENT

bidder

GOLDMAN SACHS ASSET MANAGEMENT

LIFESCI VENTURE PARTNERS

bidder

LIFESCI VENTURE PARTNERS

THE INVUS GROUP LLC

bidder

THE INVUS GROUP LLC

CASDIN CAPITAL

bidder

CASDIN CAPITAL

CORMORANT ASSET MANAGEMENT

bidder

CORMORANT ASSET MANAGEMENT

PAVILION CAPITAL

bidder

PAVILION CAPITAL

CREACION VENTURES

bidder

CREACION VENTURES

ALEXANDRIA VENTURE INVESTMENTS

bidder

ALEXANDRIA VENTURE INVESTMENTS

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - Goldman Sachs Asset Management led a $150m Series B funding round in MOMA Therapeutics.